Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9101781 | 1.00 | KDM4E (0.52) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL7597289 | 0.83 | KDM4E (0.52) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL7597293 | 0.83 | KDM4E (0.52) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL14898033 | 0.81 | KDM4E (0.50) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL29999634 | 0.80 | KDM4E (0.49) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL2558135 | 0.79 | ALDH1A1 (0.44) | KDM4EHSD17B10HPGDALDH1A1MEN1 | |
| SCHEMBL6369128 | 0.77 | KDM4E (0.44) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL6369131 | 0.77 | KDM4E (0.44) | KDM4EALOX5HSD17B10HPGDMAPK1 | |
| SCHEMBL31417827 | 0.77 | MAOB (0.60) | HPGDALDH1A1CYP3A4MEN1LMNA | |
| SCHEMBL23135186 | 0.76 | KDM4E (0.58) | KDM4EALOX5HSD17B10HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| EP-2646429-B1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646429-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012075115-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | KDM4E 1448/4885ALOX5 898/4885HSD17B10 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.